JAMA Network July 6, 2020
Kevin P. O’Callaghan, MB, BCh, BAO; Allison M. Blatz, MD; Paul A. Offit, MD

The coronavirus disease 2019 (COVID-19) pandemic has unleashed major and substantial changes in the provision of health care, including public health policy and the practice of medicine, and in the ways most individuals live their lives.1 Significant changes also have occurred in vaccine development, with shortening the usual 15- to 20-year timeline to one that might be as short as 1 to 1.5 years.2 COVID-19, the acute illness due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, Hubei province, China, in December 2019, and rapidly progressed to a global pandemic. By June 27, 2020, a total of 9.76 million people had been infected with this virus and 492 000 had died. Although widespread quarantine, isolation, and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma, Pharma / Biotech, Public Health / COVID
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing
ETH develops AI algorithm for drug discovery based on 3D protein surface
Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & more

Share This Article